Viewing StudyNCT00077558



Ignite Creation Date: 2024-05-05 @ 11:33 AM
Last Modification Date: 2024-10-26 @ 9:09 AM
Study NCT ID: NCT00077558
Status: COMPLETED
Last Update Posted: 2010-03-10
First Post: 2004-02-10

Brief Title: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions & Keywords Data

Conditions:
Name
MyelodysplasticMyeloproliferative Diseases
Leukemia
Myelodysplastic Syndromes
Keywords:
Name View
adult acute myeloid leukemia with t1517q22q12 View
accelerated phase chronic myelogenous leukemia View
blastic phase chronic myelogenous leukemia View
relapsing chronic myelogenous leukemia View
previously treated myelodysplastic syndromes View
secondary myelodysplastic syndromes View
refractory chronic lymphocytic leukemia View
recurrent adult acute lymphoblastic leukemia View
prolymphocytic leukemia View
refractory anemia with excess blasts View
chronic myelomonocytic leukemia View
recurrent adult acute myeloid leukemia View
secondary acute myeloid leukemia View
adult acute minimally differentiated myeloid leukemia M0 View
adult acute monocytic leukemia M5b View
adult acute erythroid leukemia M6 View
adult acute megakaryoblastic leukemia M7 View
adult acute myeloblastic leukemia with maturation M2 View
adult acute myeloblastic leukemia without maturation M1 View
adult acute myelomonocytic leukemia M4 View
adult acute monoblastic leukemia M5a View
adult acute promyelocytic leukemia M3 View
adult acute eosinophilic leukemia View
adult acute basophilic leukemia View
atypical chronic myeloid leukemia View
myelodysplasticmyeloproliferative disease unclassifiable View
adult acute myeloid leukemia with t821q22q22 View
adult acute myeloid leukemia with t1616p13q22 View
adult acute myeloid leukemia with inv16p13q22 View
adult acute myeloid leukemia with 11q23 MLL abnormalities View